Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.